Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16.05. | Adagio Medical Holdings, Inc. GAAP EPS of -$0.51 | - | Seeking Alpha | ||
ADAGIO MEDICAL Aktie jetzt für 0€ handeln | |||||
17.04. | Why Adagio Medical Holdings (ADGM) Stock Is Skyrocketing | 6 | Benzinga.com | ||
17.04. | Adagio Medical wins FDA breakthrough nod for cryoablation tech | 3 | MassDevice | ||
02.04. | Adagio Medical Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
31.03. | Adagio Medical Holdings reports Q4 results | 2 | Seeking Alpha | ||
27.03. | Adagio Medical Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
27.03. | Adagio Medical Holdings, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
17.03. | Adagio Medical Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
28.02. | Cryoablation developer Adagio Medical lays off staff, refocuses on US study | 2 | FierceBiotech | ||
28.02. | Adagio Medical to restructure, reduce workforce | 2 | MassDevice | ||
28.02. | Adagio Medical Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
05.02. | Adagio Medical Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
04.02. | Adagio Medical Holdings, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
14.01. | Adagio Medical Holdings, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
06.01. | Adagio Medical Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
14.11.24 | Adagio Medical Reports Third Quarter 2024 Results | 161 | Business Wire | LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the "Company" or "Adagio"), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias... ► Artikel lesen | |
31.07.24 | Adagio Medical Announces the Closing of the Business Combination with ARYA IV, Creating a Publicly Traded Company Focused on the Innovative Technologies for Treatment of Cardiac Arrhythmias | 222 | Business Wire | LAGUNA HILLS, Calif. & NEW YORK--(BUSINESS WIRE)--Adagio Medical, Inc. ("Adagio Medical"), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, announced... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
FRESENIUS MEDICAL CARE | 48,300 | +0,52 % | BERENBERG stuft FMC FRESENIUS MEDICAL CARE AG auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Fresenius Medical Care (FMC) von 55 auf 60 Euro angehoben und die Einstufung auf "Buy" belassen. Analystin Victoria Lambert... ► Artikel lesen | |
DRAEGERWERK | 67,10 | +0,15 % | Dräger-Aktie legt um 0,15 Prozent zu (67,10 €) | Im deutschen Wertpapierhandel liegt das Wertpapier von Dräger zur Stunde im Plus. Der jüngste Kurs betrug 67,10 Euro. Das Wertpapier von Dräger verzeichnet aktuell ein Kursplus von 0,15 Prozent. Es... ► Artikel lesen | |
THERMO FISHER | 349,20 | +0,13 % | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply | Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstration... ► Artikel lesen | |
STRATEC | 26,800 | -0,56 % | STRATEC zieht wieder auf dem Parkett ein | Am 9. Mai war STRATEC wegen nicht rechtzeitig erfolgter Vorlage des testierten Jahresabschlusses aus dem SDX entfernt worden. Und nun, dank des Rückzugs des Softwareanbieters COMPUGROUP von der Börse... ► Artikel lesen | |
SERNOVA BIOTHERAPEUTICS | 0,109 | +3,81 % | Sernova Biotherapeutics, Inc.: Sernova Appoints Jonathan Rigby as Interim Chair | LONDON, Ontario and BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its... ► Artikel lesen | |
FAMICORD | 4,180 | 0,00 % | Original-Research: FamiCord AG (von Montega AG): Kaufen | Original-Research: FamiCord AG - von Montega AG 06.06.2025 / 17:08 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group. Für den Inhalt der Mitteilung... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 0,745 | -2,49 % | Atossa Genetics Year-end 2024 slides: (Z)-endoxifen shows promise, expenses decline | ||
PING AN HEALTHCARE | 0,946 | +1,42 % | PA GOODDOCTOR (01833): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 JUNE 2025 | ||
DENTSPLY SIRONA | 13,565 | -0,29 % | Dividendenbekanntmachungen (27.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGC INC JP3112000009 105 JPY 0,6216 EUR ALERUS FINANCIAL CORPORATION US01446U1034 0,21 USD 0,1795 EUR ALICO INC US0162301040 0... ► Artikel lesen | |
ORGANON | 8,522 | +1,24 % | Dividendenbekanntmachungen (12.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADT INC US00090Q1031 0,055 USD 0,0478 EUR ALAMOS GOLD INC CA0115321089 0,0342 CAD 0,0218 EUR ALIBABA GROUP HOLDING LTD ADR US01609W1027 1... ► Artikel lesen | |
MOUNTAIN VALLEY MD | 0,014 | -5,41 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
CO-DIAGNOSTICS | 0,242 | +2,54 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
SONIC HEALTHCARE | 14,822 | +2,00 % | SONIC HEALTHCARE LIMITED: Change in substantial holding | ||
CYTOSORBENTS | 1,028 | -0,19 % | Cytosorbents Corp: CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb-ATR | PRINCETON, N.J., June 24, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
VERU | 0,565 | +9,51 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen |